Our name is about honesty. The Monitor is owned by The Christian Science Church, and we’ve always been transparent about that.
The Church publishes the Monitor because it sees good journalism as vital to progress in the world. Since 1908, we’ve aimed “to injure no man, but to bless all mankind,” as our founder, Mary Baker Eddy, put it.
Here, you’ll find award-winning journalism not driven by commercial influences – a news organization that takes seriously its mission to uplift the world by seeking solutions and finding reasons for credible hope.
Explore values journalism About us
One of five pharmaceutical companies on the Top 10 list, Paris-based Sanofi-Aventis put $6.3 billion toward R&D, only a 0.2 percent increase from the preceding year. In 2009, the company launched a new program to drive R&D, adding 18 partnerships and licensing agreements and two new acquisitions. Sanofi-Aventis's portfolio is 60 percent biological products and 55 percent external research.
Your subscription to The Christian Science Monitor has expired. You can renew your subscription or continue to use the site without a subscription.
If you have questions about your account, please contact customer service or call us at 1-617-450-2300.
This message will appear once per week unless you renew or log out.
Your session to The Christian Science Monitor has expired. We logged you out.
If you have questions about your account, please contact customer service or call us at 1-617-450-2300.
You don’t have a Christian Science Monitor subscription yet.
If you have questions about your account, please contact customer service or call us at 1-617-450-2300.
